People

Damantha Boteju is published by Configit as Chief Product and Technology Officer, CPTO. Joined Configit in March 2023. Over 25 years' experience in software development focusing on enterprise class products. Exact joining days are unverified unless separately sourced.

Lene Linde is published by Configit as Chief Human Resources Officer, CHRO. Joined Configit in 2017. Over 25 years in working with HR and leadership in international growth companies, including engineering, software and IT. Exact joining days are unverified unless separately sourced.

Torben Jespersen is published by Configit as Chief Operating Officer, COO. Joined Configit in 2018. Holds a Master´s Degree in Business Administration from Copenhagen Business School. More than 20 years' experience within Consulting and Consulting Management. Exact joining days are unverified unless separately sourced.

Anne Dorthe Gyldenkærne is published by Configit as Chief Marketing Officer, CMO. Joined Configit in 2020. The Chartered Institute of Marketing Degree, Oxford. Master of Science (MSc) in Public Administration (cand. scient. adm.). More than 20 years' experience in the B2B software marketing space working in international growth companies. Exact joining days are unverified unless separately sourced.

Alessio Ciulli chairs TRIMTECH’s scientific advisory board. His Dundee research focuses on targeted protein degradation, including VHL-binding ligands and PROTAC ternary-complex structures. He co-founded Amphista Therapeutics and leads Dundee’s Centre for Targeted Protein Degradation.

William (Will) McEwan is an academic co-founder and chief scientific adviser at TRIMTECH. He leads a UK Dementia Research Institute group at Cambridge exploring antiviral mechanisms and protein aggregation in neurodegenerative disease. The company identifies his research alongside Leo James’s as a foundation for its TRIM21 platform.

Anders Tang Christensen is published by Configit as Chief Financial Officer, CFO. Joined Configit in 2016. Over 30 years in finance with more than 17 years of experience in financial and operational leadership of high growth software companies. Exact joining days are unverified unless separately sourced.

Johan Salenstedt is published by Configit as Chief Executive Officer, CEO. Joined Configit in September 2019. Over 30 years of experience in executive leadership positions in high growth software companies such as IBM, Adobe and Qlik. Exact joining days are unverified unless separately sourced.

Leo James is a TRIMTECH academic co-founder, chief scientific adviser and scientific advisory board member. He leads research at the MRC Laboratory of Molecular Biology and is a Fellow of the Royal Society. His work established key mechanisms of TRIM21 and contributed to Trim-Away protein-degradation technology.

Alison Lawton independently chairs TRIMTECH’s board. Her biopharmaceutical leadership experience includes Kaleido Biosciences, Aura Biosciences, Genzyme and Sanofi. She has served on several public and private biotechnology boards and has extensive regulatory and market-access experience.

Minjie (MJ) Yu is published as MJ Yu in Cercano’s current venture-capital roster. His self-named public profile identifies Cercano Management in Singapore. The specific current global platform office is not published in the retrieved roster.

Published as Tommy Teo in Cercano’s current venture-capital roster. Singapore’s regulator identifies Tommy Teo Zhi Zhuang as CEO and Executive Director of Cercano Management Asia Pte. Ltd.; this subsidiary office is distinct from his qualified global platform affiliation. Nera Telecommunications’ own 2023 annual report identifies the full name and describes his role leading Cercano’s Singapore investment team.

Joel Shoop serves as Chief Operating Officer. He is responsible for all financial and operational aspects of Cercano’s investment structuring, execution, valuation, reporting, treasury, and tax functions, paired with oversight of the firm’s information and technology strategy. Prior to joining Cercano, he served as the Head of Direct Structured Credit Finance for Castlelake, L.P. and held various oversight roles. Prior to Castlelake, Joel served in various leadership and managerial positions within finance and operations at MUFG Investor Services focused on fund administration and at Deloitte within the audit practice. He received his Master of Accountancy and BS from the University of Wisconsin-Madison and is a CPA.

Rick Roberts is on the investment team with a focus on fintech, venture capital, and private equity. Before Cercano, Rick initiated research coverage on public and private companies globally at Vulcan Capital. Prior to Vulcan, Rick was a consultant to asset management firms and a senior partner at First Quadrant. He has been directly involved in the investment industry for over 30 years and spent his formative years at Bankers Trust and regional banks. Rick received his MBA from the University of Notre Dame and earned a BS in agriculture from the University of Arizona.

Stuart Nagae is the Co-Head of Venture Capital at Cercano. Prior to Cercano, Stuart was an investor at Vulcan Capital from 2002-2021. At Vulcan, Stuart invested across a range of asset classes including private equity, growth equity, wireless spectrum and venture capital. Before Vulcan, Stuart worked as an investment banker at Hambrecht & Quist and JPMorgan Chase & Co. Stuart received a BA in international relations from Stanford University.

Malinda Khauv serves as Cercano’s Chief Compliance Officer. In this role, Malinda is responsible for implementing and overseeing Cercano’s core compliance program functions. Prior to joining Cercano, Malinda served as Chief Compliance Officer at Freestone Capital Management, helping define and manage the firm’s compliance program. Malinda also held a senior compliance position at IQ-EQ. Malinda earned a BA from the University of St. Thomas and an MBA from the University of Washington. She also holds the Investment Adviser Certified Compliance Professional (IACCP®) designation.

Albert Hwang serves as the Co-Head of Private Investments. Prior to Cercano, Albert was a senior investment professional at Vulcan Capital where he led private investments. He previously served in governance roles as director, observer, or advisor at several portfolio companies. Prior to Vulcan, Albert began his career at Jefferies & Company in the leveraged finance department. Albert holds a BS in economics from The Wharton School at the University of Pennsylvania.

Kim Holte serves as Chief Financial Officer of Cercano Management. She leads Cercano’s global finance function, including accounting, financial reporting, budgeting and forecasting, and financial controls. She also oversees all internal accounting financial operations. Prior to joining Cercano in 2021, Kim served as a senior manager at Baker Tilly, a nationwide public accounting firm. Kim is a licensed CPA and holds a BS in both Accounting and Finance from the University of Wisconsin La Crosse.

Trish Halper is currently the Co-Chief Investment Officer at Cercano. Prior to Cercano she was the Chief Investment Officer for the Global Family and Private Investment Offices at Northern Trust, responsible for over $50 billion in advisory assets. She also served as Deputy Chief Investment Officer at Wespath Benefits, overseeing a $30 billion multi asset class investment portfolio. Previously, she spent over twenty years at Chicago Equity Partners, a boutique quantitative asset management firm, as a quant researcher, portfolio manager, and Chief Investment Officer. Trish is a CFA charterholder and holds a MS in financial mathematics from the University of Chicago and a BS in mathematics from Loyola University Chicago.

YB Choi is Co-Head of Venture Capital at Cercano Management. Prior to joining Cercano, he served as a Director of Venture Capital at Vulcan Capital, leading investments and portfolio oversight for more than 50 companies across a broad range of industry sectors. Before Vulcan, he began his career as an analyst at Cowen & Co. before moving to Oppenheimer & Co. Inc., then later served as Manager in IP Acquisitions and Investments at Microsoft. YB received a BS in engineering and management systems from Columbia University.

Michelle Brant is the Head of Human Resources, leading the company’s recruitment, development, total rewards, engagement, and retention strategies. Prior to Cercano Michelle served as the Director of HR at Vulcan Capital. Before Vulcan, she worked at Alaska Air Group, with both Alaska Airlines and Horizon Air. Michelle earned a BBA degree from the Foster School of Business at the University of Washington.

Chris Orndorff is the Chief Executive Officer and Co-Chief Investment Officer of Cercano Management. Prior to founding Cercano in 2021, Chris was the Chief Investment Officer at Vulcan Capital, a private company started by Microsoft co-founder Paul G. Allen. Before Vulcan, Chris was a Senior Portfolio Manager at Western Asset, a Managing Principal at Payden & Rygel, and Second Vice President at Northern Trust. Chris currently serves on the board of directors for Bank OZK, one of the largest commercial real estate lenders. Chris holds an MBA from the University of Chicago, and a BS from Miami University. He is a CFA charterholder, and has published several monographs, including a book published by McGraw-Hill.

Dean Clift leads biology at TRIMTECH. Following his Edinburgh doctorate, he worked at Cambridge’s MRC Laboratory of Molecular Biology with Melina Schuh and Leo James. His research helped establish Trim-Away technology and investigate activation of the TRIM21 ubiquitin ligase.

Andrea Testa is TRIMTECH vice president of chemistry and a scientific co-founder of Amphista Therapeutics. His targeted-protein-degradation experience includes work in Alessio Ciulli’s Dundee laboratory and developing oral, brain-penetrant degraders at Amphista. He holds an Aberdeen doctorate and a Milan chemistry master’s.

Alex Alanine heads chemistry at TRIMTECH. His background includes more than two decades at Roche, neuroscience medicinal chemistry leadership, and the COO role at Nanna Therapeutics before its acquisition by Astellas. He earned his doctorate at Leeds and has advised biotechnology discovery programmes.

Nicola (Nicki) Thompson is CEO of TRIMTECH Therapeutics. She previously founded and led Amphista Therapeutics and held drug-discovery and business-development leadership roles at Roche and GSK. Her experience includes Nanna Therapeutics, Camena Bioscience and Syntaxin; the current company biography also identifies her as Nascent Therapeutics board chair.

Alexander James Stevens is the current registered statutory director of NielsenVenturesUKLimited, company13302973, appointedJune10,2026 according toCompaniesHouse. The UK company is associated with2xN’s earlier published founding/operating people; this legal affiliation does not assert a2xN investment-management title or identify him with the separate PlanetAVentures professional namedAlexanderStevens. A genuine matching public portrait and further professional biography were not verified.

Kris Kaczmarek joined2xN as QuantumInvestmentAssociate inMarch2023. He previously headed product at ORCAComputing, developing its quantum-memory technology through Oxford doctoral research. His employer-published biography describes photonics research at Geneva,Oxford,Warsaw andICFO. QDNLParticipations announced his move asInvestmentDirector onOctober29,2024, corroborated by his own departure post, so his2xN role is historical.

Evgenia Sopochkina was published as2xN Principal after joining inApril2021. Her primary biography describes RoundHillVentures experience, founding an AI talent-management startup, and finance work at Barclays, BNPParibas andCreditAgricole. She holds HECParis management and LondonBusinessSchool MBA qualifications. Later primary professional announcements publish EvgeniaMacpherson with the same2xN/AI-startup/education background. Her2xN affiliation is dated because the old directory is hidden and later employer roles exist; an unverified current title is not asserted.

Johan Maunsbach was published as2xN Partner and COO in its earlier directory and2023 European Quantum Technology Conference. Qualified as a lawyer in Sweden and England and Wales, he spent a decade at PartnersGroup and previously served as GPBullhound Partner/COO. His original biography describes private-market transaction management and an Uppsala LL.M. His current DMXPartners biography identifies the2xN role as prior; CompaniesHouse confirms his associated UK statutory directorship endedJune19,2026, so the operating affiliation is qualified as historical.

Niels Nielsen co-founded2xN and leads its quantum-technology investment focus. He was an early Cambridge Quantum investor and chairman before its merger with Honeywell Quantum Solutions into Quantinuum, where he became a board member. His primary biography describes experience building financial-services businesses including Zedra, Vistra and LGTVestra and ownership in AzureHotels. He holds a Brown business/economics degree and a Yale MBA. Institutional2xN investments are distinguished from his personal investments and other family-office businesses.

Co-head of BNP Paribas Asset Management Alts’ Agility Co-Invest strategy. The June 29, 2026 final-close announcement identifies his leadership of the European mid-cap private equity co-investment programme alongside Lionel Gomez.

Co-head of BNP Paribas Asset Management Alts’ Agility Co-Invest strategy. The June 29, 2026 final-close announcement identifies his leadership of the European mid-cap private equity co-investment programme alongside Damien Fournier.

Head of Real Assets for BNP Paribas Asset Management Alts, published in the September 7, 2026 European Junior Infrastructure Debt Fund II final-close announcement. The platform’s infrastructure debt strategy finances energy transition, clean mobility, digital infrastructure and utilities.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Clinical Ophthalmology specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Global health specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Global health specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Diabetes, business development/commercial specialist and investor. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Oncology specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Cardiology specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Investor, Entrepreneur, Operator and Board Member. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Global Head of Private Equity for BNP Paribas Asset Management Alts. The same current management card also names him CEO of the separate BNPP AM Prime platform; the Prime office is kept as context rather than an Alts legal-entity employment claim.

Wende Hutton is a healthcare venture investor named to Mission Bay Capital’s outside investment advisory committee. Canaan’s own biography identifies her general-partner investing in therapeutics and medical devices, following earlier Mayfield investing and operating roles at GenPharm and Nellcor. She studied human biology at Stanford and earned an MBA at Harvard. Mission Bay’s published committee role is outside advice, not presumed fund employment or a personally funded company check.

John Wadsworth Jr is named in Mission Bay Capital’s public investment advisory committee, whose undated directory describes his outside Manitou Ventures managing-director affiliation. UCSF’s October2009 fund launch names John Wadsworth and Brook Byers as leaders of its pro bono advisory committee. This record concerns the investment adviser in that exact institutional context, not unrelated Wadsworth names. The affiliation is advisory and does not establish employment, a fund commitment or a personal company investment.

Lennart Mucke serves on Dolby Family Ventures’ scientific advisory board. His research examines mechanisms of memory loss and neurological dysfunction in Alzheimer’s disease and related disorders. His published biography describes leadership at Gladstone’s neurological-disease institute and UCSF neuroscience and neurology appointments, with earlier clinical and neurobiology training in Germany and the United States. The advisory role is distinct from executive management of the investment firm.

Michál de Beer joined Dolby Family Ventures in2026 as an analyst supporting its frontier-technology fund. He earned an economics bachelor’s degree at the University of California, Berkeley and interned at Bank of America Merrill Lynch and Rand Merchant Bank. The firm’s biography describes his student-athlete rugby achievements and Johannesburg background. An exact appointment day is not disclosed.

Alona Cochran is office manager and executive assistant at Dolby Family Ventures. The firm dates her work with it to2014 while employed by Levensohn Venture Partners, which she joined in2006. Her earlier experience includes executive assistance in J.P. Morgan’s technology, media and telecom investment-banking group and other financial-services firms. She earned a business-administration bachelor’s degree at the University of San Francisco.

Mei Liang is vice president of finance at Dolby Family Ventures, which dates her arrival to2024. She previously worked as financial controller and senior vice president at Riverwood Capital and held corporate-finance roles covering reporting and internal controls. Earlier she worked in Arthur Andersen’s assurance and business-advisory practice. She earned an accounting bachelor’s degree from Santa Clara University.

Usua Amanam is a senior associate at Dolby Family Ventures supporting technology and climate investments. He joined in2023 as an associate, after energy-transition investment work at NGP Energy Capital Management and consulting at PowerAdvocate. He holds Stanford bachelor’s, master’s and doctoral degrees in energy resources engineering. His doctoral research addressed chemical kinetics, nanocatalysts and nanoparticle transport.

Carsten Gjørtler Salling, professionally also Carsten Salling, is named as general partner in Dreamcraft’s legacy own media kit and in executive-board/board capacities in its primary signed2022 manager accounts. The exact full name is present in the digital-signature execution section. His absence from the current Dreamcraft four-partner roster is explicitly qualified; no current2026 employment or exact ending day is inferred.

Pascal Levensohn is executive chairman of Dolby Family Ventures. He joined in2014 after advising the family’s direct technology portfolio since2012. He founded Levensohn Venture Partners and has experience in investment management and venture-company governance. His current own biography dates his appointment as chair of Cambridge University Innovation Hub’s Global Advisory Board to April2026; his National Venture Capital Association directorship was2007–2011.

Christian Kirk Rasmussen is a founding partner in Dreamcraft’s own legacy media kit and a named director in its signed2022 manager annual report. Better Collective’s current own press kit identifies him as co-founder/co-CEO and publishes the original portrait retained here. His absence from Dreamcraft’s current four-partner site means continued current partnership status is not inferred; no exact ending date is published in reviewed primary sources.

René Rechtman is a current Dreamcraft partner, joining its published partnership with Nikolaj Nyholm. He is founder and CEO of Moonbug Entertainment according to its own2024 issuer announcement. Better Collective’s primary2023 annual report provides his authentic original caption-bound portrait and identifies an MSc in Politics and International Relations from Copenhagen University, prior Walt Disney/Maker Studios leadership and earlier AOL, Goviral and TradeDoubler roles. Historical board roles remain dated; no personal check is inferred.

Nikolaj Nyholm is a current partner in Dreamcraft’s own four-person partnership. His own announcement describes joining with René Rechtman to support founders with direct audience/community relationships across gaming, media, sports, music and infrastructure. The primary Astralis2021 annual report provides his caption-bound original portrait and dated chairman biography; historical Astralis roles are not presented as current2026 employment.

Jesper Søgaard is a current Dreamcraft partner and founding partner in its own legacy media kit. He is also co-founder and co-CEO of Better Collective, whose own press kit supplies his genuine original portrait. Better Collective’s primary annual reports identify his Copenhagen University MSc in Political Science and founding-member role at Dreamcraft Ventures Management ApS. He is a named manager director in signed2022 accounts; these institutional roles do not establish a personal investment ticket.

Daniel Mariussen is a current partner at Dreamcraft in Copenhagen/London and was a general partner in its earlier own media kit. The manager’s signed2022 annual report uses Daniel Nyvang Mariussen on its governance pages and Daniel Nyvang-Székely Mariussen in the execution signatures, providing the full/short-name bridge. He serves in the manager’s executive board and board in that dated document. His quoted operational venture-engineering approach and historical Kvantify board capacity are distinct from individual cash participation.

Vivian Dang is an accounting and financial-operations professional published as controller at Mission Bay Capital, where its biography says she joined in2010 and provides part-time CFO services. She previously served as controller at Mohr Davidow Ventures and worked in tax and audit at Andersen and Deloitte. She earned an accounting degree at the University of California Riverside. Her financial-operations practice and part-time support role are distinguished from full-time investment-partner employment.

Onn C. Lee leads shared corporate accounting that includes Alexandria’s venture portfolio. She joined Alexandria in 2009 and became EVP in March 2022, with exact days unverified. Her earlier work was in Deloitte assurance. She is a CPA and studied economics and accounting at UCLA. This support remit does not establish investment-partner authority.

Blake L. Stevens oversees Alexandria’s Research Triangle venture portfolio and national agtech investment strategy, alongside regional real-estate leadership. His EVP promotion was in January 2026. Earlier positions include LaunchLabs management, investing at Harris & Harris, and technical work at HZO. He holds materials-science degrees from Cornell and Northwestern.

Jenna Foger manages Alexandria’s venture portfolio and Strategic Capital Platform as a life-science co-lead. She became EVP in January 2026 after earlier leadership roles beginning in 2014. Her background includes Windham venture investing, consulting and Rockefeller neurobiology research; she studied biotechnology at Columbia and neuroscience/psychology at Penn.

Hallie E. Kuhn co-leads Alexandria’s life-science activities and oversees venture investments alongside capital-markets duties. Her current EVP appointment dates to January 2026, with the precise day unverified. She previously worked at LS Polaris and ClearView. Her education includes a Harvard systems-biology doctorate and Harvey Mudd bachelor’s degree.

Silvano Garnerone publicly announced joining Wingbits as Head of Data Science. The appointment is directly published by him; current membership and exact start date are unverified.

Jeff Wilson is published by Wingbits as Head of Product and Commercial Services, with expertise in ADS-B, aircraft surveillance and commercial aviation data services.

Yanal Hammouda leads market expansion according to Wingbits’ published biography, working on international growth, market entry and localization.

Ray Buckton is credited as Marketing in Wingbits’ published author biography, covering its network and community developments. Current employment status is unverified.

Wingbits co-founder with a software engineering background. Its founder biography labels him CTO/CEO of operating company Airbits, while structured company data labels him CEO.

Wingbits co-founder. Its visible founder biography labels him CEO; structured company data labels him CCO. The current title conflict is unresolved.

Debojyoti Mahapatra is published by QMill as Team member (role not published). Own companySeptember2026posts explicitly identify his participation in the QMill booth and quote him about the event. Exact job title is not published in these sources.

Jouni Peltonen is published by QMill as Team member (role not published). Own companySeptember2026posts explicitly call him a colleague and quote his job at QMill alongside a University of Jyväskylä PhD. Exact job title is unpublished in the reviewed company sources.

Juha Koponen is published by QMill as Senior Quantum Product Manager. Own individual profile reposts QMill appointment announcement; own companySeptember2026post also identifies him as a colleague demonstrating QMill technology. Distinct from other JuhaKoponen professionals, none native matched.

Elias Vakkuri is published by QMill as Software Engineer. Software, cloud, digital strategy and AI/ML experience; MSc in industrial engineering and management from Tampere University.

Ernesto Campos is published by QMill as Quantum Algorithms Engineer. Quantum-computing PhD researching variational algorithms, tensor networks and quantum-classical machine learning; prior teaching and research at ÉTS Montreal and Monterrey Institute of Technology.

Tommi Tenkanen is published by QMill as Head of Business Development and Strategy. Current own companySeptember2026conference announcement publishes exact title; theoretical-physics and strategy background is corroborated by the event organizer.

Janne Heikkinen is published by QMill as Chief Product Officer. Own June2026company hackathon report identifies ChiefProductOfficer; participants and winning students are external, not employees.

Clayton Leite is published by QMill as Quantum AI Engineer. Researches AI-driven quantum-circuit design and optimization. Own technical blog establishes affiliation, and co-founder repost quotes the original company post publishing QuantumAIEngineer title.

David Karpuk is published by QMill as Principal Quantum Algorithm Engineer. Develops the mathematics behind practical quantum algorithms for noisy intermediate-scale hardware; previous academic and data-science experience.

Sami Oksanen is published by QMill as Head of Sales. Sales and business-development experience in ICT and energy industries; own company blog says he joined in April2025. Current own2026company posts retain Head of Sales.

Toni Annala is published by QMill as Chief Algorithm Engineer and Co-Founder. Mathematician with published appointments at the Institute for Advanced Study, Princeton, University of Chicago and University of Toronto, and recipient of the2023CMSBlairSpearmanPrize.

Mikko Möttönen is published by QMill as Chief Scientist and Co-Founder. Professor of Quantum Technology at Aalto University and co-founder of quantum-computer hardware company IQM; active quantum research and technology commercialization.

Ville Kotovirta is published by QMill as Chief Technology Officer and Co-Founder. Previously led the quantum algorithms and software team at VTT Technical Research Centre of Finland.

Hannu Kauppinen is published by QMill as Chief Executive Officer and Co-Founder. Former Nokia Technologies CTO and Head of Nokia Research Center; co-founder of location-technology company Quuppa.

Takahiro Mukohira, commonly published as Tak Mukohira, is cofounder and CEO of TNAX Biopharma, which he has led since its March 2018 founding. TNAX’s own biography confirms his former President role at MP Healthcare Venture Management, the Boston corporate venture arm of Mitsubishi Tanabe Pharma. He previously led business development at Life Science Institute in the Mitsubishi Chemical group and has more than 35 years of pharmaceutical and healthcare experience spanning business development, corporate strategy and international business. He earned an SM in Management of Technology from MIT Sloan and a BS in Pharmaceutical Sciences from Kyoto University. His MPH presidency is historical; its exact tenure dates are not established from these primary biographies.

Tetsuro Iwata, also published as Tetsu Iwata, was Senior Manager at MP Healthcare Venture Management from July 2009 to August 2015 according to his own professional chronology. The primary RESI 2014 conference biography independently names his MPH role and July 2009 start and describes prior pharmaceutical business-development, licensing, sales, marketing and project-management responsibilities, including cardiovascular, stroke, renal and respiratory areas. He studied pharmaceutical sciences at Meiji Pharmaceutical University. Later roles at Mitsubishi Tanabe Pharma and its US holding company are distinct from his historical MPH investment role. No current MPH title or personal investment is inferred, and month-only dates remain without invented days.

Naoya Sato formerly served as Director of MP Healthcare Venture Management from March 2015 to March 2019 according to his own public professional chronology. Kauffman Fellows’ primary Laura Tadvalkar biography independently identifies him as her MPH Director mentor. His earlier pharmaceutical research and management work included Mitsubishi Tanabe Pharma and Tanabe Research Laboratories USA, with autoimmune, psychiatric and neurological research using human induced pluripotent stem cells. His public profile subsequently identifies business-development work at Mitsubishi Tanabe Pharma, academic research-administration work at Chiba University from April 2023 to February 2026, and Chief Operating Officer of TOKIWA-Bio from March 2026. This is a historical MPH role, not an assertion of current employment; month-only dates remain unconverted to invented days.

Shota Ozawa was a Director at MP Healthcare Venture Management from June 2023 to June 2026 according to his own public professional profile. LiberoThera’s August 1, 2024 primary financing announcement independently names him as MPH Director when he joined that company’s board. His profile places him in Tanabe Pharma’s Transformation Division from July 2026, following earlier research and business-development positions at Mitsubishi Tanabe Pharma. His education includes medicine at Kyoto University, biophysics and biochemistry at the University of Tokyo and an MBA at UMass Lowell. AMED’s current registered-VC list still names him as an MPH contact; this registration is qualified against the subsequent employment chronology, rather than presented as proof of a current Director appointment. Source employment dates are month-only.

Lilly deSouza Burr is published by Novocuff as Director (issuer July2024; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Curt LaBelle is published by Novocuff as Director (issuer July2024; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Shacey Petrovic is published by Novocuff as Chair of the Board (issuer July2024; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Lisa Tehrani is published by Novocuff as Director of Marketing (own legacy page; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Rich Ferrick is published by Novocuff as Quality Assurance. This role is listed on the company’s current own team page.

Marissa VanDeVeer is published by Novocuff as Clinical Engineer. This role is listed on the company’s current own team page.

Jane Price is published by Novocuff as Clinical Research Manager. This role is listed on the company’s current own team page.

Vaishali Suraj is published by Novocuff as Sr. Director of Clinical Affairs. This role is listed on the company’s current own team page.

Kathryn Wine is published by Novocuff as VP of Clinical Affairs. This role is listed on the company’s current own team page.

Donald Lee is published by Novocuff as Co-founder & COO. This role is listed on the company’s current own team page.

Amelia “Amy” Degenkolb is Novocuff’s co-founder and CEO. The current company roster publishes Amy Degenkolb; the issuer’s Series A announcement explicitly supplies the Amelia/Amy alias.

T. Denny Sanford was a businessman, life-sciences investor and philanthropist. EnBiotix’s original2021 financing announcement identifies Sanford Biosciences LLC as his life-sciences investment arm. His professional biography records University of Minnesota graduation1959, industrial distribution/manufacturing entrepreneurship, and the1986 purchase of a Sioux Falls bank followed by United National Corporation, First Premier Bank and Premier Bankcard. He supported biomedical research and education at multiple legally separate institutions. Sanford Burnham Prebys confirms he diedJuly18,2026. His private investor affiliation is historical; charitable donations and company checks are not conflated, and no current succession manager is inferred.

Isabel Cardoso is named as Head of Back and Middle Office in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.

Paul Watel is named as Investment Manager in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.

Olivier Tak is publicly named by ALS Investment Fund as science and due diligence. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Alexandre Heraud is named as Partner in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.

Nancy de Ruiter is publicly named by ALS Investment Fund as chair — advisory committee. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Jeroen van der Pol is publicly named by ALS Investment Fund as chief financial officer. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Michelle Meijerink is publicly named by ALS Investment Fund as compliance. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Siya Chandrie is publicly named by ALS Investment Fund as investor relations. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

François Santi is named as Partner in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.

Rist Brouwer is publicly named by ALS Investment Fund as advisor — investment committee. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Craig Boyce is a managing partner of ALS Investment Fund. Its December 2025 announcement describes more than 25 years of private-equity experience, including a former managing-director role at Bain Capital, and a longstanding commitment to ALS academic research and patient services.

Jacob Tutor is publicly listed as Manager in the Amgen Ventures section of Amgen Business Development’s current team directory. The venture team invests in emerging healthcare, biotechnology and digital-technology companies and provides access to Amgen scientific and development expertise. His published corporate affiliation is distinguished from personal investing; education, earlier career and appointment date are not disclosed in the reviewed primary card.

Joshua Crapser, PhD, is publicly listed by Amgen Business Development as Manager in the Amgen Ventures team. The corporate venture function identifies and supports healthcare and tech-bio innovators through equity capital and access to Amgen drug-development capabilities. His professional affiliation and doctoral designation are sourced from the current own named team card; prior employers, doctorate institution and personal investment activity are not established by that directory.

Gladys Nunez is currently listed by Amgen Business Development as Executive Director, Ventures. Portfolio company Casma describes responsibility for venture diligence, deal execution and portfolio board-observer work, and a career at Amgen beginning in1997, spanning laboratory research and business development. She previously conducted research at AstraZeneca and Amgen. Her published education comprises an MSc in biochemical pharmacology from Southampton and a BSc from Marist College. Her current own corporate title is used instead of older principal/director titles.

Rachna Khosla joined Amgen in2013 and became Senior Vice President of Business Development in September2021. Her corporate remit expressly includes Amgen Ventures alongside M&A, licensing, search/evaluation and alliance management. She previously held corporate-development roles at Amgen and healthcare M&A roles at Lazard, Credit Suisse, Sanofi/Aventis, J.P. Morgan and Salomon Brothers. She holds a BA from Barnard College and an MBA from Columbia Business School. The venture oversight affiliation is distinguished from a dedicated venture investing title.

Christophe Pieri is published as Impact Investing Portfolio Manager / AxClimat Fund Manager by Ambra Capital. The own fund article identifies him as manager of AxClimat I, focused on European decarbonisation fund investments.

Alexandre Pelletier is published as Venture Partner — CapHorn venture brand by the CapHorn venture-capital brand. He joined CapHorn in2017 following more than15 years of international operating experience, including Microsoft and Tata Communications.

Huaizheng Peng, styled Peng Huaizheng in the CMS directory, is China Medical System’s published chief business officer. After serving as an independent non-executive director from May2010 to October2013, he continued working with the group. His prior career includes life-science investment roles in UK and Canadian financial firms. He earned clinical-medicine degrees at Hunan Medical College in1984 and1989 and a molecular-pathology doctorate at UniversityCollegeLondon in1998, and taught histopathology there. SEC2019 separately names him director of the HongKong investment vehicle and chief executive of distinct A&BHK; he signs CMSHK’s2022 Gelesis filing as director. Those dated subsidiary roles are not inferred from his present parent-group title.

Lam Kong founded China Medical System and is identified in its own current directory as chairman, chief executive and president. He directs the group’s development strategy and has a medical and pharmaceutical-commercial background. He studied clinical medicine at Zhanjiang Medical College, graduating in1986. SEC2019 identifies him separately as director of CMS Medical Venture Investment(HK), and sole director/indirect owner of the distinct A&B corporate investment entities. Subsidiary roles are source-qualified historical; no personal investment check is inferred from control of corporate buyers.

Flora Coppolani is published as Managing Partner — CapHorn venture brand by the CapHorn venture-capital brand. She joined CapHorn in2022 following experience at Bpifrance and Rocket Internet and manages its venture team.

Pierre Lainé is published as Director of Venture Capital Portfolio by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Olivier Budin is published as Asset Manager by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Caroline Seillier is published as Senior Portfolio Manager by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Fabien Krésac is published as Senior Investment Manager by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Vincent Lachene is published as Director of Development by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Deepak Asudani is a UC San Diego clinical professor and hospital-medicine physician with expertise in public health, applied genomics and medical management. gMendel announced his board appointment on May29,2023, and its2023 review described his work on health systems and US expansion. This records a historical published board affiliation; current membership is not asserted.

Lars Staal Wegner is a physician, AI-biotechnology executive and former Evaxion CEO. gMendel announced his appointment as board chairman effective November1,2022 and included him in its January2023 presentation. Its current directory names Zoran Zdraveski as chairman, so the gMendel affiliation recorded here is historical.

Ken Ndugga-Kabuye was listed in gMendel’s January2023 company presentation as US Market Advisor. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Marija Andrileou was listed in gMendel’s January2023 company presentation as Marketing and Communications. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Wouter Hamel was listed in gMendel’s January2023 company presentation as Advocacy and Sales Development. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Agnieszka Tymoszyk was listed in gMendel’s January2023 company presentation as Quality Assurance. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Dariusz Nablotczyk was listed in gMendel’s January2023 company presentation as Software Architect. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Marija Chaushevska was listed in gMendel’s January2023 company presentation as AI Researcher. This records a dated professional affiliation; continuing2026 employment is not confirmed.

David Galevski was listed in gMendel’s January2023 company presentation as Data Scientist. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Kristijan Jankoski was listed in gMendel’s January2023 company presentation as Senior Data Scientist. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Karmele Alapont Celaya was listed as a genomics researcher in gMendel’s January2023 presentation. Company-hosted2024–2025 publications bridge the shorter Karmele Alapont name to her full name. This is a dated research affiliation; continuing2026 employment is not confirmed.

Anne Kristine Schack was listed in gMendel’s January2023 company presentation as Genomics Researcher. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Tomas Puk was listed in gMendel’s January2023 company presentation as Head of Quality by Design. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Aleksandar Nikov was listed in gMendel’s January2023 company presentation as Head of AI. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Hanna Pyokari is a gMendel co-founder identified in its January2023 presentation and2023 review. The company announced her board appointment effective November1,2022. She holds economics and business-administration and CEMS qualifications, with experience in pharmaceuticals and financial planning. The signed2022 annual report uses her full name Hanna Marjaana Pyökäri. This board affiliation is historical; continuing2026 membership is not asserted.

Johan Leonhard is gMendel’s legal adviser and an attorney and partner at Nyborg & Rørdam. His published background covers intellectual property, data protection and commercial and company law, including earlier in-house counsel and data-protection responsibilities.

Lukasz Krych is gMendel’s genomic adviser and an associate professor in food science at the University of Copenhagen. His research includes molecular assays, sequencing protocols and high-throughput quantitative PCR.

Zoran Zdraveski chairs gMendel’s board. A biochemistry PhD with chemistry and law qualifications, he is a biopharmaceutical legal and intellectual-property executive at TScan Therapeutics, with earlier Magenta and Epizyme experience. The company announced his board appointment in May2023; its January2023 presentation records an earlier strategic-adviser capacity.

Antonina Burlachenko leads regulatory and quality assurance at gMendel, under the published title CRQA. She has an electronics and acoustics master’s degree and more than a decade of regulatory and quality experience in diagnostics, overseeing compliance and quality-management work.

Dimitrios Kyriakidis is gMendel’s Chief Commercial Officer. His published biography describes sales and marketing qualifications and medical-device commercial experience at Stryker and Johnson & Johnson. The earlier company presentation lists him as Dimitri Kyriakidis in advocacy and sales development.

Gjorgji Madjarov is gMendel’s Chief Artificial Intelligence Officer and a professor at Ss. Cyril and Methodius University. His background is in computer science, information technology, advanced AI and machine-learning algorithms. The January2023 presentation records an earlier AI-adviser capacity.

Carmen Garrido Navas is gMendel’s Chief Scientific Officer. A genetics PhD, her published biography describes research supervision and teaching at the University of Granada. The earlier company presentation lists her clinical-evaluation responsibilities.

Zoran Velkoski is gMendel’s CTO and co-founder. He holds qualifications in embedded systems and business administration and has extensive entrepreneurship and product-development experience in deep technology. The current company directory and signed annual report confirm Velkoski; Velkovski appears only in the original portrait filename.

Chris Kyriakidis is gMendel’s CEO and co-founder. He holds a doctorate, a master’s in physics and an MBA, with earlier international healthcare experience at Novo Nordisk and GN. The signed company annual report and LRQA certificate identify the same executive as Christos Kyriakidis. Quaternity ApS’s signed2025 annual statements also identify him under his legal name Christos Kyriakidis as its director; the June25,2026 signature is evidence of that documented governance position, not an inferred personal financing allocation.

Aja Guldhammer Henderson is published by Antler as Nordics Operating Partner.

Anna Munthe-Kaas is published by Antler as Associate Partner, Oslo.

Balder Eklöf Eira is published by Antler as Investment Team.

Leo Philippsthal is published by Antler as Platform & Community.

Gill Hauzmann is published by Antler as Investment Team.

Clara Reich is published by Antler as Investment Team.

Markus Lukk is published by Antler as Investment Team.

Rahim Shah is published by Antler as Controller.

McKenzie Hagan is published by Antler as Senior Manager, Scouting.

Helen Park is published by Antler as Director, Platform.

Kaila Lim is published by Antler as Director, Community.

Sam Blumenthal is published by Antler as Principal.

Jake O'Shea is published by Antler as Principal.

Cash Allred is published by Antler as Senior Principal.

Caroline Healey is published by Antler as Senior Principal.

Rio Hodges is published by Antler as Associate Partner.

Lisa Potocsnak is published by Antler as Partner, Finance & Operations.

Rakesh Sah is published by Antler as Finance Manager.

Bazil Azmil is published by Antler as Principal.

Richard Baillie is published by Antler as Principal.

Darren Murphy is published by Antler as Vice President.

Sarah Finegan is published by Antler as Associate Partner.

Alannah Roche is published by Antler as Investment Associate.

Theresa Hoffmann-Mogev is published by Antler as Investment Manager.

Aaron Sotunde-Adesina is published by Antler as Associate.

Ifelayomi Odubawo is published by Antler as Finance Associate.

Daniel Chenube is published by Antler as Associate.

Teddy Himler is published by Antler as Venture Partner.

Sebastien Wakim is published by Antler as Venture Partner.

Omar Chihane is published by Antler as Venture Partner.

Mo Ghahroudi is published by Antler as Venture Partner.

Maximilian Plank is published by Antler as Venture Partner.

Marc Weill is published by Antler as Venture Partner.

Manav Daryanani is published by Antler as Venture Partner.

Malik Alyousef is published by Antler as Venture Partner.

Jonathan Labin is published by Antler as Venture Partner.

John Mady is published by Antler as Venture Partner.

Jerry Gamez is published by Antler as Venture Partner.

Florian Jansen is published by Antler as Venture Partner.

Edward Goff is published by Antler as Venture Partner.

Beau Seil is published by Antler as Venture Partner.

Baghdad Gherras is published by Antler as Venture Partner.

Ashish Jain is published by Antler as Venture Partner.

Amer Mkhalalati is published by Antler as Venture Partner.

Adam Jaffer is published by Antler as Advisor.

Wafaa Al Obaidat is published by Antler as Venture Partner.

Ammar Zaidi is published by Antler as Senior Finance Associate.

Saim Riaz is published by Antler as Investment Analyst.

Rana Taher is published by Antler as Investment Associate.

Minos Minas is published by Antler as Gaming Lead.

Karan Teckchandani is published by Antler as Investment Manager.

Mohamed Hamza is published by Antler as Director, Investments.

Hala Ebrahim is published by Antler as Associate Partner.

Halah Al Jubeir is published by Antler as Managing Director (KSA).

Ha Phan is published by Antler as Growth & Marketing Associate Director.

Najla Zamri is published by Antler as Investment Director.

Soyeon Kim is published by Antler as Marketing Analyst.

Hailey Hyewon Song is published by Antler as Program Manager.

Sujin Lee is published by Antler as Portfolio Manager.

Doori Jung is published by Antler as Finance Manager.

Juyeop Kwon is published by Antler as Senior Analyst.

Heechan Kim is published by Antler as Senior FX Manager.

Roy Junyoung Jang is published by Antler as Associate Director.

Ashish Patel is published by Antler as Fractional CTO.

Leila Trulsen is published by Antler as Investment Manager.

Pulkit Srivastava is published by Antler as Venture Partner.

‍Kosen Kenta is published by Antler as Investment Principal.

Kaito Nozawa is published by Antler as Program Manager.

Satomi Hoshi is published by Antler as Startup Scouting Manager.

Jordan Fisher is published by Antler as Venture Partner.

Florian Geier is published by Antler as Senior Director.

Audrey Gunawan is published by Antler as Senior Finance Associate.

Keith Lim is published by Antler as Finance Director.

Zahra is published by Antler as Finance Associate.

Olivia Irish is published by Antler as Scouting Associate.

Lorenzo Peracchione is published by Antler as Venture Partner.

Renu Halepaty is published by Antler as Executive Assistant.

Himank Amar is published by Antler as Analyst.

Raghav Chopra is published by Antler as Associate.

Dravisha Katoch is published by Antler as Associate.

Vignesh Prasad is published by Antler as Associate.

Raghav Goyal is published by Antler as Manager.

Sankalp Sharma is published by Antler as Manager.

Anshul Tibrewala is published by Antler as Head of Marketing.

Afroz Dairkee is published by Antler as Director.

Jasnoor Gill is published by Antler as Director.

Gowri Shankar is published by Antler as Associate Partner.

Daphne McLarty is published by Antler as Principal.

Alex Wright is published by Antler as Principal.

João Braga is published by Antler as Fund Ops Analyst.

Samuel Barbu is published by Antler as Finance Director.

Beatriz Montiani is published by Antler as Investment Director.

Imogen Jones is published by Antler as Scouting Manager.

Zahir Hassan is published by Antler as Scouting Associate.

Devna Kashyap is published by Antler as Senior Portfolio Manager.

Felipe Guedes is published by Antler as Marketing Content Producer.

Leila Oliveira is published by Antler as Senior Investment Manager.

Rachel Guest is published by Antler as Senior Manager, Program.

Min Tan is published by Antler as Finance, Director.

Stefan Knight is published by Antler as Director, Queensland.

Behdad Shahsavari is published by Antler as Venture Partner.

Georg Hartmann is published by Antler as Venture Partner.

Juan Galan is published by Antler as Venture Partner.

Nikolaus Föbus is published by Antler as Venture Partner.

Frederik Brandis is published by Antler as Venture Partner.

Benedikt Jaenecke is published by Antler as Investment Team.

Job Wever is published by Antler as Investment Team.

Jack Davies is published by Antler as VP MARKETING & PR. Cambridge Enterprise affiliation: Jack Davies is listed by Cambridge Enterprise as Operations Associate. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Sandeep Casi is published by Antler as Partner, Head of Ibex Japan, Global Business Development & Collaborations.

Baz Saideh is published by Antler as Partner, Business Development.

Deepak Jayaraman is published by Antler as Partner, Global Head of Business Development and Collaborations.

Joie Chan is published by Antler as Manager.

Peter Schmidt is published by Antler as Director (US).

Shalaka Uchil is published by Antler as Director.

Saina Chiba is published by Antler as Director (Japan).

Rafael Mastrocola is published by Antler as Capital Director.

Amy Zaghloul is published by Antler as Director (Middle East).

Fabian Rother is published by Antler as Director (DACH).

Matt Glossop is published by Antler as Associate Partner (Canada).

Michael Kron is published by Antler as Partner.

Yashveer Yadav is published by Antler as Associate Partner (India).

Ros Bazany is published by Antler as Partner.

Graeme Mather is published by Antler as Partner (Asia).

Will Robinson is published by Antler as Partner, Head of Strategic Partnerships.

Desmond Poon is published by Antler as Partner (UK).

Charles Hayley-Bell is published by Antler as Partner (US).

TC Høiseth is published by Antler as Partner (Europe).

Anthony Millet is published by Antler as Managing Partner.

Mathias Owing Maanum is published by Antler as Partner, Elevate.

Martell Hardenberg is published by Antler as Partner.

Romain (رومان) Assunção is published by Antler as Founder and Managing Partner.

JaeHee Chang is published by Antler as Partner.

Rufus Sorsa is published by Antler as Associate Partner.

Roslyn Jin is published by Antler as Partner, Platform & Founder Experience.

Sarah Kimmorley is published by Antler as Vice President.

James McClure is published by Antler as Partner.

Gabriel Jung is published by Antler as Partner.

Erik Jonsson is published by Antler as Partner.

Markus Bruderer is published by Antler as Partner.

Melalite Ayenew is published by Antler as Partner.

Oscar Westergård is published by Antler as Partner.

Livia Moore is published by Antler as Associate Partner.

Anil Atmaramani is published by Antler as Partner.

Michael Wiatr Aagaard is published by Antler as Partner under the name Michael J. Wiatr in its global directory and General Partner, Copenhagen in its Nordics directory. He previously worked at Boston Consulting Group and has co-founded, advised and invested in startups, including two companies that exited.

Kristian Jul Røsjø formerly worked as a Partner at Antler, helping build its Nordic investment platform and raise Nordic funds. His own departure announcement says he was leaving after eight years and that Anna Munthe-Kaas would lead the Oslo team; the exact end date is unverified.

Ronald Jan Schuurs is published by Antler as Partner.

Jed Rose is published by Antler as Partner.

Naman Budhdeo is published by Antler as Partner Emeritus.

Bernie Li is published by Antler as General Partner.

Ryan Sommerville is published by Antler as General Partner.

Antti Tormanen formerly helped build Antler’s Helsinki office as a Partner. In his own departure announcement he said he was moving on from the operating role and would remain a Venture Partner through the end of the year; the exact end date and continuing status are unverified.

Frank Kang is published by Antler as Associate Partner.

Agung Bezharie Hadinegoro is published by Antler as Partner.

Marie Nielsen is published by Antler as Partner.

Jiho Kang is published by Antler as Partner.

Marcelo Ciampolini is published by Antler as Partner.

Carolina Strobel is published by Antler as Partner.

Winnie Khoo is published by Antler as Partner.

Edward Knight is published by Antler as President.

James Anderson is published by Antler as Advisory Board Member (published global advisory board).

Todd Ruppert is published by Antler as Advisory Board Member (published global advisory board).

Ken Hitchner is published by Antler as Advisory Board Member (published global advisory board).

Peter Harrison is published by Antler as Advisory Board Member (published global advisory board).

Nancy Zimmerman is published by Antler as Advisory Board Member (published global advisory board).

David Fischer is published by Antler as Advisory Board Member (published global advisory board). This identity is distinct from existing Adex namesakes and is matched to Antler’s own biography and identity links.

Tore Myrholt is published by Antler as Co-chair.

Sheila Patel is published by Antler as Co-chair.

Adrian Dalton is published by Antler as Head of Compliance.

Daniel Fisher is published by Antler as VP Brand & Content. This identity is distinct from existing Adex namesakes and is matched to Antler’s own biography and identity links.

Nitin Sharma is published by Antler as Partner.

Rike Döpp Bergérus is published by Antler as VP, Global Communications.

Lola Masha is published by Antler as Partner.

Annabel Hodges is published by Antler as VP, Global Head of Marketing Operations.

Lotta Patrickson is published by Antler as Vice President, Head of People & Culture.

Adam French is published by Antler as Partner.

Andrea Hajdu-Howe is published by Antler as Managing Partner.

Jussi Salovaara is published by Antler as Co-founder of Antler and Asia Managing Partner.

Jussi Kallasvuo is published by Antler as Partner and, in its Nordics directory, General Partner in Helsinki.

Bob Rosin is published by Antler as Managing Partner, US.

Tobias Bengtsdahl is published by Antler as Partner and, in its Nordics directory, General Partner in Stockholm.

Hannah Leach is published by Antler as Partner.

Jeff Becker is published by Antler as General Partner.

Rajiv Srivatsa is published by Antler as Partner.

Christoph Klink is published by Antler as Partner.

Vegard Medbo is published by Antler as Co-founder & Chief Operating Officer.

Dilan Mizrakli Landgraff is published by Antler as Co-founder & Chief Strategy Officer.

Fridtjof Berge is published by Antler as Co-founder & Chief Business Officer.

Alan Poensgen is published by Antler as Partner.

Fady Abdel-Nour is published by Antler as Partner.

Frank Stevenaar is published by Antler as Chief Financial Officer.

Bede Moore is published by Antler as Chief Commercial Officer.

Lavanya Indralingam is published by Antler as Partner, Head of Global Operations.

Magnus Grimeland is published by Antler as Founder & Chief Executive Officer.

George Kroustalakis, Associate Background in AI consulting at EY, working on machine learning and data-driven solutions across industries. Passionate about scalable technologies shaping the future. BSc in Computer Science, AUEB, specializing in AI and Data Science.

Henry Umunnakwe, Platform & Ecosystem Lead Entrepreneurship ecosystem expert and founder of Athens Tech Circle. Background in Natural Gas Engineering and an MSc in Entrepreneurship from ALBA Graduate Business School, Athens.

Nancy Asimakopoulou, Associate Previously worked as Manager, handling the large-cap Private Equities at Dialectica. Loves innovative ideas that create a better future. BSc in Finance & Accounting from Athens University of Economics & Business.

Konstantinos Karvounakis, Principal, in Educational Leave Previously worked as a Business Analyst at McKinsey & Company, and has gained experience in Corporate Finance at PwC. MSc in Electrical Engineering & Computer Science from Aristotle University of Thessaloniki.

Angelos Manglis, Venture Partner Experienced consultant, engineer, and entrepreneur. Early supporter of startup financing in Greece and the region. Strategic thinker focused on exits. MSc in Technical Change and Industrial Strategy, University of Manchester.

Demetris Iacovides – Partner, Brain Gain Fund Active investor in the Greek tech ecosystem, ex-Principal at Big Pi Ventures and angel investor. Background in finance and strategy at Deloitte, PwC, and Genesis Pharma. Studied engineering, biotech, and economics at UCL, Imperial, LSE, and Grenoble EM.

George Karantonis, Partner Entrepreneur turned investor, previously co-founder of two ICT companies, also spent several years as a freelance consultant. Early participant as an operator and investor in 2 Greek NASDAQ companies. MS. in Exploration Geophysics and an MBA from ALBA.

Yorgos Mousmoulas, Partner Previously Investment Director at Attica Ventures, a Series A fund investing in IT, Telecom, Microelectronics, Automation & Robotics. Operator in technology companies and ICT strategy consultant. Electrical Engineer and INSEAD MBA.

Myrto Papathanou, Partner Finance and high tech experience in London and Athens. Loves articulate engineers and teams that can execute. Drawn to deep tech investments and industry disruptors. Multitasker, listener and connector. INSEAD MBA, Kauffman Fellow.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Medtech Startup Coach. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Co-Founder at Braingrade & Aureliym, Founder at Nemotec. The directory does not distinguish a board appointment from an advisory appointment.

Scientific adviser to Neurosoft Bioelectronics on neuro artificial intelligence and foundation brain modelling. Assistant professor at EPFL, where he leads the NeuroAI research group; founder of the Brain-Score benchmarking platform.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: General Manager of Heraeus Materials. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Former President at BioAlps Association and former CTO of Wyss Center. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Professor of Neurosurgery, University Otago and Co-Founder BRAI3N-Centre for neuromodulation, Ghent. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Professor of Intelligent Healthcare Technologies at Technische Universität Dresden. The directory does not distinguish a board appointment from an advisory appointment.

Co-founder of Neurosoft Bioelectronics. Its own team card also lists her as an EPFL full professor and Vice President for Support to Strategic Initiatives; those are external academic offices.

Michael Hoffman was appointed Avation Medical vice president of market access and payer relations in April2024. Avestria’s own portfolio update describes his remit as reimbursement, payer coverage and commercial market-access strategy for Vivally. Current employment is unconfirmed.

Darren Wennen was appointed Avation Medical chief marketing officer in April2022, responsible for marketing, sales operations and customer care ahead of commercialization. The issuer describes earlier commercial and marketing leadership at Tactile Medical and other medical-device businesses. Current employment is unconfirmed.

Raymond Huggenberger was appointed an independent director of Avation Medical in December2021. Its release identifies him as a former president and CEO of Inogen and an industry adviser to Arboretum Ventures. Current board membership is not confirmed.

Renee Selman was appointed an independent director of Avation Medical in December2021. The issuer identifies her earlier role as Worldwide President of Women’s Health and Urology at Ethicon, a Johnson & Johnson business. Current board membership is not confirmed.

Jason Whiting was appointed Avation Medical CEO in November2024. Its issuer biography describes more than 25 years in medical technology and eight years leading ZOLL Cardiac Management Solutions. Avation announced Manish Vaishya as CEO in March2026.

Manish Vaishya is Avation Medical’s co-founder, CEO and board member. He led the development of the Vivally wearable neuromodulation system through clinical trials, FDA 510(k) clearance and commercialization. The company publishes more than 25 years of medical-technology experience and a PhD in mechanical and systems engineering, MBA in international marketing, and BSc from IIT Kanpur.

Susan L-J Dickinson is AFTD’s former chief executive officer, leading the charity from2008 until retirement in May2026. She is a genetic counselor with an Arcadia University master’s degree and Swarthmore biology/psychology undergraduate education. Her professional work supported communication among researchers, clinicians and the public, expansion of FTD research programmes and development of support services. A stale translated staff directory identifies her former role and authentic portrait; current English staff and Summer2026 leadership sources confirm Rachel Biblow succeeded her. The historical affiliation is not represented as current leadership.

Valdemar Langsager is publicly listed by CVX Ventures as Venture Analyst. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Stella Blicher is publicly listed by CVX Ventures as Marketing Associate. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Shakib Ghaderi is publicly listed by CVX Ventures as Partner Relations. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Steve Olesen is publicly listed by CVX Ventures as Partner Relations. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

George Chapipis is publicly listed by CVX Ventures as Partner Relations. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Jacob Søhoel is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Mathias Sønke Pedersen is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Kim Drud Abildgaard is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Mikkel Graae Pedersen is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Oscar Thybo heads Board & Investment at CVX Ventures; his separate own biography describes the Board & Advisory function. He matches companies with experienced partners and has a Copenhagen Business School business-economics background, including a semester in Singapore. He previously spent five years at Flyhjælp, managing a 22-person department and working on business development, partnerships, finance and a company sale. He hosts Vækstmaskinen and participates in startup pitch panels.

Zenia W. Francker is publicly listed by CVX Ventures as Director. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Willem-Jan Wollants is named Scientist – Droia Labs in Droia’s current public directory. The published professional background includes Bioengineer, KU Leuven; IBD research group, KU Leuven; Labmanager at Flamingo Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Evelien Verdrengh is named Office Manager & Executive Assistant in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Jens Van fraeyenhove is named Investment Analyst in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Nele Vandervoort is named Senior Scientist – Droia Labs in Droia’s current public directory. The published professional background includes M.Sc. Biomedical Sciences KU Leuven; Former senior scientist at Galapagos NV and Augustine Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Matthew Vander Heiden is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Associate Professor in the Department of Biology at the Massachusetts Institute of Technology; Associate Director of the Koch Institute for Integrative Cancer Research; Institute Member of the Broad Institute of Harvard and MIT; Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Nathan Tops is named Business Development Analyst in Droia’s current public directory. The published professional background includes Master in Biochemistry & Biotechnology - KU Leuven; Master in Management - INSEAD; Investment Fellow - Ackermans & van Haaren; Business Development intern - Engine Biosciences; Market Access intern - AxTalis. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Simona Talpau is named Accountant in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Joris Souffreau is named Senior Technician – Droia Labs in Droia’s current public directory. The published professional background includes M.Sc. Biology Ghent University; Labtechnician at Center for Cancer Biology (CCB), VIB, Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Kathleen Sonck is named Principal Scientist – Droia Labs in Droia’s current public directory. The published professional background includes M.sc. in Bioengineering (cel and gene biotechnology), KU Leuven; Ph.D. in Bioengineering, Centre of Microbial and Plant Genetics, KU Leuven; Former senior scientist at Galapagos NV and Aelin Therapeutics; (Antimicrobial, Cystic Fibrosis and lung fibrosis drug development experience). This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

A. Campbell Sullivan is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Texas San Antonio. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Hendrik P.N. Scholl is named Investment Advisory Board in Droia’s current public directory. The published professional background includes M.D. University of Tübingen; Professor and Chairman of the Department of Ophthalmology, University of Basel; Founding and Scientific Director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB); Retinal specialist with expertise in translational research in ophthalmology, especially gene therapy. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Emily Rogalski is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Northwestern/University of Chicago. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Eric Rowinsky is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Executive Chairman of RGenix, Inc; Board Member at Biogen, Navidea, Fortress Biotech, Verastem; Chief Medical Office/Scientific Advisor: Hummingbird Biosciences, Oncotartis, Lokon; Oncology Advisor, Everest Medicines. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Kristoffer Rhoads is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Washington. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sergio Quezada is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Professor of Cancer Immunology and Immunotherapy at UCL Cancer Institute; Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory; CRUK Senior Cancer Research Fellow; Co-leading scientist CRUK Cancer Immunotherapy Accelerator; CSO at Achilles Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Kate Possin is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of California, San Francisco. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Magdalini Polymenidou is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Zurich. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sara Morren is named Chief of Staff to Managing Partner in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Olivier Piguet is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Sydney. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Xin-An Lin is named VP Finance in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Mary O’Hara is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Colorado. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Darby Morhardt is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Northwestern University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Guy Eelen is named VP R&D – Droia Labs in Droia’s current public directory. The published professional background includes PhD in Medical Sciences, KU Leuven; FWO postdoctoral fellow; Postgraduate Business Administration, KU Leuven; Former senior staff, Center for Cancer Biology (CCB), VIB, Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Leonard van den Berg is a QurAlis clinical adviser and motor-neuron disease researcher associated with Utrecht and the Dutch ALS centre. His training includes medical studies in Groningen, doctoral research at Utrecht and a fellowship at Columbia.

Lauren Massimo is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Pennsylvania. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Allison Lindauer is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Oregon Health & Science University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Alexander Depauw is named General Counsel in Droia’s current public directory. The published professional background includes Master of Laws, University of Ghent and University of Copenhagen; LL.M in International Financial Law, King’s College London; Lydian; De Cronos Groep. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Maya Lichtenstein is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Geisinger Health. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Dame Pamela Shaw is a QurAlis clinical adviser and neurological researcher at the University of Sheffield. Her work centres on motor-neuron disease and the Sheffield Institute for Translational Neuroscience.

Mathias De Decker is named Senior Associate in Droia’s current public directory. The published professional background includes PhD Biomedical Sciences, Molecular Neurosciences, University of Leuven; FWO Doctoral Research at Lab of Neurobiology (VIB), University of Leuven; M. Sc. Bioengineering, Cell and Gene Technology, University of Leuven; Internship at Biocartis. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Tammaryn Lashley is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University College London. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Mathias Declercq is named Principal in Droia’s current public directory. The published professional background includes PhD Biomedical Sciences, University of Leuven; Doctoral Research at Angiogenesis and Vascular Metabolism lab (VIB) and Woman & Child unit, Cystic Fibrosis lab (KU Leuven/UZ Leuven); MSc Biochemistry-Biotechnology, University of Leuven; MSc Management, University of Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Celeste Karch is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Washington University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Nathalie De Blieck is named Director of Accounting in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

David Irwin is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Pennsylvania. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Ammar Al-Chalabi is a QurAlis clinical adviser and King’s College London professor studying ALS genetics and clinical disease. His current university biography identifies leadership of its Motor Neuron Disease Care and Research Centre and co-direction of the UK MND Research Institute, with work on Project MinE and the UK MND register.

Jo Bury is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Master in pharmaceutical sciences, UGent; PhD Biochemistry, UGent; MBA, Vlerick School for management; Founder of VIB; Managing Director VIB 1995-2022; Non executive director of companies and research institutions. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Maya Henry is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Texas Austin. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Katleen Brepoels is named Senior Technician – Droia Labs in Droia’s current public directory. The published professional background includes Bachelor Pharmaceutical and Biological Techniques Ghent; Senior labtechnician at Center for Cancer Biology (CCB), VIB, Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Nupur Ghoshal is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Washington University in St. Louis. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sophie Bernier is named Compliance Manager in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Tania Gendron is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Miami. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Brian Wainger, MD, PhD, is a QurAlis scientific adviser whose neurological research spans patient-derived cell models, ALS and pain. His training includes Princeton, Columbia and Massachusetts General Hospital, with research at Boston Children’s Hospital and Harvard.

Roderick Beijersbergen is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Group leader at the Netherlands Cancer Institute; Head of the NKI Robotics and Screening Center; Expert in large scale functional genomics; Pioneer of pooled screening technology; Co-founder of Qameleon Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Fen-Biao Gao is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Massachusetts. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Tirtha Chakraborty is named Venture Partner in Droia’s current public directory. The published professional background includes Ph.D. in Molecular Biology from TIFR, Mumbai, India; Trained at Yale, NIH and Harvard in RNA metabolism, genetic engineering and immunology; mRNA platform lead, Moderna Therapeutics; Head of Hematology, CRISPR Therapeutics; VP of Cell Therapy, Sana Biotechnology; CSO and Head of Tech Ops, Vor Bio; SAB member at Specific Biologics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Bernhardt Trout is a QurAlis scientific adviser and MIT chemical-engineering professor. His research combines pharmaceutical manufacturing, physical chemistry and computational methods; he trained at MIT and Berkeley and undertook postdoctoral work at the Max Planck Institute.

Mark S. Forman is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Ventyx Biosciences. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sebastian Bernales is named Venture Partner in Droia’s current public directory. The published professional background includes BA in Biochemistry, Catholic University in Chile; PhD in Cell Biology, UCSF; Medivation; Praxis Biotech; Merken Biotech. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Jamie Fong is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Baylor University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Matthias Van Woensel is named Partner in Droia’s current public directory. The published professional background includes M. Sc. Biomedical Sciences, University of Leuven; PhD Biomedical Sciences – Tumor Immunology, University of Leuven; PhD Pharmaceutical Sciences – Polymers, ULB; PhD fellow IWT; Recipient VCU RDD Peter R. Byron Graduate Student Award; Belgian Brain Tumor Support. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Christopher Shaw is a QurAlis scientific adviser and neurologist at King’s College London studying ALS genetics. His research includes disease-associated TARDBP and FUS mechanisms, following doctoral training at Cambridge; he is distinct from the real-estate professional of the same name already in Adex.

Howard Feldman is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of California, San Diego. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

George Golumbeski is named Partner in Droia’s current public directory. The published professional background includes BA in Biology, University of Virginia; PhD in Genetics, University of Wisconsin-Madison; Novartis; Celgene (Bristol Myers Squibb); Arch Venture Partners; Board member Acceleron Pharma, Sage Therapeutics, Carrick Therapeutics, Shattuck Labs and others. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Fayron Epps is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Emory University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Luc Verelst is named Founder & Chairman in Droia’s current public directory. The published professional background includes M.Sc. Bio-Engineering, University of Leuven; Founder / former owner of Verelst real estate group; Seasoned investor in small and big biotech, venture capital; Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Dennis Dickson is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Mayo Clinic Florida. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Janwillem Naesens is named Managing Partner Oncology & Droia Group in Droia’s current public directory. The published professional background includes M.Sc. Engineering, University of Leuven; MBA, INSEAD; McKinsey & Company; Waterland Private Equity. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Richard Ryan Darby is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Vanderbilt University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Kevin Eggan, PhD, co-founded QurAlis and serves on its scientific advisory board. He is a stem-cell and neurodegeneration researcher whose career includes Harvard and the Broad Institute and later BioMarin research leadership; he trained at the University of Illinois, MIT and the Whitehead Institute.

Sudhir Agrawal is a scientific adviser to QurAlis and a specialist in antisense and nucleic-acid therapeutics. His work includes founding Idera and Arnay Therapeutics and academic collaboration with the University of Massachusetts Medical School.

Sami Barmada is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Michigan. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred. Sami Barmada is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Director, Michigan Brain Bank and Neurology Associate Professor at University of Michigan Medical School. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Jalayne J. Arias is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Georgia State University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Howard Rosen is listed by AFTD as External Medical Advisory Council Member; Education Committee Chair. Its published professional affiliation is University of California, San Francisco. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

John Sims, MD, is a QurAlis director affiliated with Eli Lilly. His career combines neurological clinical research with drug-development leadership, including Lilly work on donanemab, prior Harvard/Massachusetts General Hospital research and a Dartmouth medical degree.

Carmela Tartaglia is listed by AFTD as External Medical Advisory Council Chair Elect. Its published professional affiliation is University of Toronto. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Chiadi Onyike is listed by AFTD as External Medical Advisory Council Chair (2025–2028). Its published professional affiliation is Johns Hopkins University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Helen-Ann Comstock is publicly listed by AFTD as Founder; Historical Board Member (2002–2025). She founded AFTD in2002 and previously directed the Southeastern Chapter of the Alzheimer’s Association. She served on the AFTD board from2002 until her death on July30,2025; her founder and board affiliation is explicitly historical.

Abrar Tanveer is publicly listed by AFTD as Board Member. His published professional background includes health-technology startups following Ohio State graduation2017 and a Venture for America fellowship2018.

Margaret Sutherland is publicly listed by AFTD as Board Member. Her professional biography identifies a Chan Zuckerberg Initiative Neurodegeneration Challenge Network programme-management role, earlier NINDS programme leadership2007–2019, and academic pharmacology posts. She earned a Cambridge molecular-biology PhD and trained at Baylor.

Kristin Schneeman is publicly listed by AFTD as Board Member. She directs innovation work at FasterCures, part of the Milken Institute, focusing on research funding, collaboration and translation of treatments.

Anne Clem Whitaker chairs the QurAlis board. She has held senior commercial and executive roles at Sanofi, GlaxoSmithKline, Bausch Health and Aerami Therapeutics, and studied chemistry at the University of North Alabama.

David Pfeifer is publicly listed by AFTD as Board Member. He is president of Anderson Mason Dale Architects and a University of Cincinnati design, architecture, art and planning graduate.

Vikas Sharma, PhD, leads business development as chief business officer of QurAlis. His prior roles include BioXcel Therapeutics, MacroGenics, Rexahn and MedImmune/AstraZeneca; he trained in immunology at Rutgers and microbiology in Mumbai.

Girish Patangay is publicly listed by AFTD as Board Member. He leads Chan Zuckerberg Initiative central technology teams supporting science and education. His previous decade at Meta involved infrastructure, developer tools and AR/VR products; AFTD also identifies prior technical advice to the FTD Disorders Registry.

Manoj Malhotra, MD, is chief medical officer of QurAlis. Previously a neuroscience and eye-care medical-affairs leader at AbbVie and CMO at Ovid Therapeutics, he trained at Wayne State University and the Cleveland Clinic and has clinical and development experience across neurological and rare diseases.

Kathy Newhouse Mele is publicly listed by AFTD as Board Member. Her professional experience includes elementary and English-as-a-second-language teaching and chairing the Angel Shine Foundation for dance education.

Daniel (Dan) Elbaum, PhD, is chief scientific officer of QurAlis, with experience in medicinal chemistry and rare-disease drug discovery. His career includes Pfizer, Amgen, Kinetix, FoldRx and Retrophin, following Harvard chemistry training and postdoctoral work at the University of Pennsylvania.

Joseph Marquez is publicly listed by AFTD as Board Member. He is a Seattle urologist and multispecialty-practice department founder. He studied at UC Santa Cruz and Northwestern medicine, with residency training at Minnesota.

Hagen Cramer, PhD, is chief technology officer of QurAlis and an oligonucleotide chemistry and manufacturing specialist. His prior work includes Wave Life Sciences, Girindus and Nitto Denko Avecia, following chemistry doctoral training at Konstanz and postdoctoral research at the NIH.

Jary Larsen is publicly listed by AFTD as Board Member. He is a licensed neuropsychologist affiliated in the published biography with UCSF/ZSFG and the VA Northern California Cognitive Neuropsychology and Electrophysiology laboratory. His earlier AFTD board2010–2017 and chair2013–2016 service is historical.

Jason Brown is CFO and COO of QurAlis. He previously led finance at Karuna Therapeutics and held financial responsibilities at PureTech Health and Novartis; he holds a Hamilton College degree and a Boston College MBA.